Publications by authors named "Pierre Gabai"
Clin Kidney J
October 2024
Article Synopsis
- Elexacaftor/tezacaftor/ivacaftor (ETI) is a new treatment for cystic fibrosis that significantly improves lung health, but its effects on kidneys remain uncertain.
- A study involving 19 adults with cystic fibrosis showed no significant change in kidney function after 7 months of ETI treatment, though there was a decrease in aldosterone levels and magnesuria.
- The results indicate that ETI does not negatively affect renal function in the short term and may help address related issues like hyperaldosteronism; however, further research is needed to understand the implications for kidney stone risk.
